Cure My Disease

Don't miss your cure!

Home News Browse Soon ready About
Log in / Sign up
← Back to home

Epicrispr Biotechnologies, Inc.

Clinical trials sponsored by Epicrispr Biotechnologies, Inc., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

  • Experimental gene 'Silencer' therapy enters human testing for rare muscle disease Results expected Jul 2027 (estimated)
Browse trials soon ready across all sponsors →
Not yet finished but already full! 1
Sort by
  • Experimental gene 'Silencer' therapy enters human testing for rare muscle disease

    Disease control Ongoing

    This early-phase trial is testing EPI-321, a one-time gene therapy designed to silence the faulty gene that causes facioscapulohumeral muscular dystrophy (FSHD). The study will enroll 12 adults with FSHD Type 1 to see if the treatment is safe and tolerable, and whether it shows a…

    Phase 1/2 • Sponsor: Epicrispr Biotechnologies, Inc. • Aim: Disease control

    Last updated Aug 21, 2026 00:00 UTC

Cure My Disease

Helping patients find clinical trials that match their disease.

Why was Cure my disease built?

Explore

Home News Browse Glossary About Terms of use Contact us

This is a site from Cyber and Space